PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Ginkgo Bioworks Holdings, Inc. (DNA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US37611X1000

CUSIP

37611X100

Sector

Healthcare

IPO Date

Apr 19, 2021

Highlights

Market Cap

$552.37M

EPS (TTM)

-$12.89

Total Revenue (TTM)

$217.95M

Gross Profit (TTM)

$138.89M

EBITDA (TTM)

-$607.14M

Year Range

$5.26 - $74.00

Target Price

$8.20

Short %

22.28%

Short Ratio

6.40

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
DNA vs. PLTR DNA vs. ARDX DNA vs. POWW DNA vs. VIR DNA vs. VOO DNA vs. INVZ DNA vs. WBA DNA vs. SPY DNA vs. VTI DNA vs. MRNA
Popular comparisons:
DNA vs. PLTR DNA vs. ARDX DNA vs. POWW DNA vs. VIR DNA vs. VOO DNA vs. INVZ DNA vs. WBA DNA vs. SPY DNA vs. VTI DNA vs. MRNA

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Ginkgo Bioworks Holdings, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%JulyAugustSeptemberOctoberNovemberDecember
-97.51%
42.46%
DNA (Ginkgo Bioworks Holdings, Inc.)
Benchmark (^GSPC)

Returns By Period

Ginkgo Bioworks Holdings, Inc. had a return of -85.09% year-to-date (YTD) and -85.68% in the last 12 months.


DNA

YTD

-85.09%

1M

58.49%

6M

-40.62%

1Y

-85.68%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

24.34%

1M

0.23%

6M

8.53%

1Y

24.95%

5Y*

13.01%

10Y*

11.06%

Monthly Returns

The table below presents the monthly returns of DNA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-28.40%25.62%-23.68%-23.18%-40.69%-36.75%13.67%-55.99%21.82%-6.50%14.17%-85.09%
202315.38%-24.62%-9.52%-8.27%29.51%17.72%34.95%-6.77%-22.65%-24.31%-5.84%31.01%0.00%
2022-28.04%-24.75%-10.44%-28.04%6.21%-22.73%20.17%-5.94%15.99%-12.50%-27.11%-15.08%-79.66%
20211.19%-3.61%0.91%-0.90%1.01%16.25%19.24%-14.11%-29.99%-17.89%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of DNA is 8, meaning it’s performing worse than 92% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of DNA is 88
Overall Rank
The Sharpe Ratio Rank of DNA is 99
Sharpe Ratio Rank
The Sortino Ratio Rank of DNA is 44
Sortino Ratio Rank
The Omega Ratio Rank of DNA is 77
Omega Ratio Rank
The Calmar Ratio Rank of DNA is 44
Calmar Ratio Rank
The Martin Ratio Rank of DNA is 1717
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Ginkgo Bioworks Holdings, Inc. (DNA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for DNA, currently valued at -0.83, compared to the broader market-4.00-2.000.002.00-0.832.10
The chart of Sortino ratio for DNA, currently valued at -1.82, compared to the broader market-4.00-2.000.002.004.00-1.822.80
The chart of Omega ratio for DNA, currently valued at 0.80, compared to the broader market0.501.001.502.000.801.39
The chart of Calmar ratio for DNA, currently valued at -0.86, compared to the broader market0.002.004.006.00-0.863.09
The chart of Martin ratio for DNA, currently valued at -1.23, compared to the broader market-5.000.005.0010.0015.0020.0025.00-1.2313.49
DNA
^GSPC

The current Ginkgo Bioworks Holdings, Inc. Sharpe ratio is -0.83. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Ginkgo Bioworks Holdings, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JulyAugustSeptemberOctoberNovemberDecember
-0.83
2.10
DNA (Ginkgo Bioworks Holdings, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Ginkgo Bioworks Holdings, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-98.31%
-2.62%
DNA (Ginkgo Bioworks Holdings, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Ginkgo Bioworks Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Ginkgo Bioworks Holdings, Inc. was 99.10%, occurring on Sep 9, 2024. The portfolio has not yet recovered.

The current Ginkgo Bioworks Holdings, Inc. drawdown is 98.31%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.1%Nov 10, 2021710Sep 9, 2024
-28.69%Sep 28, 202110Oct 11, 20216Oct 19, 202116
-11.76%Apr 26, 202198Sep 13, 20213Sep 16, 2021101
-11.28%Oct 20, 20213Oct 22, 202111Nov 8, 202114
-8.78%Sep 20, 20211Sep 20, 20213Sep 23, 20214

Volatility

Volatility Chart

The current Ginkgo Bioworks Holdings, Inc. volatility is 35.69%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%JulyAugustSeptemberOctoberNovemberDecember
35.69%
3.79%
DNA (Ginkgo Bioworks Holdings, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Ginkgo Bioworks Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Ginkgo Bioworks Holdings, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab